financetom
Business
financetom
/
Business
/
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Jun 14, 2024 2:54 PM

(Reuters) - The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.

(Reporting by Puyaan Singh in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Petroleum Refineries Major Phillips 66 Shares Are Falling Today
Why Petroleum Refineries Major Phillips 66 Shares Are Falling Today
Apr 26, 2024
Phillips 66  shares are trading lower after it reported first-quarter FY24 results. Revenue of $36.436 billion exceeded the consensus of $33.075 billion. Adjusted EPS of $1.90 missed the consensus of $2.17. Midstream segment adjusted pre-tax income stood at $613 million, vs. $754 million in the fourth quarter of fiscal 2023. The Chemicals segment adjusted pre-tax income stood at $205 million vs. $106 million in the prior...
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apr 26, 2024
10:30 AM EDT, 04/26/2024 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the European Medicines Agency. The application is for intravitreal pegcetacoplan to treat geographic atrophy, a leading cause of blindness. The company said...
Archrock Extends Share Repurchase Program, Maintains Quarterly Dividend
Archrock Extends Share Repurchase Program, Maintains Quarterly Dividend
Apr 26, 2024
10:29 AM EDT, 04/26/2024 (MT Newswires) -- Archrock ( AROC ) said Friday its board has extended its share repurchase program for an additional two-year period and maintained its quarterly dividend. The extended buyback program has an available capacity of $50 million. The program was originally set to expire Saturday, the company said. The $0.165 per share dividend is payable...
Mexico's FEMSA revenues climb 11% on Oxxo, Coca-Cola growth
Mexico's FEMSA revenues climb 11% on Oxxo, Coca-Cola growth
Apr 26, 2024
MEXICO CITY, April 26 (Reuters) - Mexico's FEMSA, which controls one of the largest Coca-Cola bottlers and a string of convenience store chains, posted an 11% increase in revenue in the first quarter, boosted by growth across nearly all its business sectors. Revenue came in at 178.20 billion pesos ($10.78 billion) in the three-month period, largely in line with expectations,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved